Ketamine: Therapeutic potential versus recreational misuse

Abstract

Get full access to this article

View all access options for this article.

References

Barrios

Connolly

Ferris

, et al. (2025) Ketamine use in a large global sample: Characteristics, patterns of use and emergency medical treatment. J Psychopharmacol 39. DOI: 10.1177/02698811241273850.

Chang

Juruena

Young

(2024) Ketamine cystitis following ketamine therapy for treatment-resistant depression—Case report. BMC Psychiatry 24: 9.

Gent

Bryan

Cleary

, et al. (2024) Esketamine combined with a mindfulness-based intervention for individuals with alcohol problems. J Psychopharmacol 38: 541–550.

Glue

Neehoff

Beaglehole

, et al. (2024) Ketamine for treatment-resistant major depressive disorder: Double-blind active-controlled crossover study. J Psychopharmacol 38: 162–167.

Gutiérrez-Rojas

Vendrell-Serres

Ramos-Quiroga

, et al. (2025) Compassionate use of esketamine intranasal in patients with severe major depressive disorder resistant to the treatment. J Psychopharmacol 39: 2698811241267837. DOI: 10.1177/02698811241267837.

Ingrosso

Cleare

Juruena

(2025) Is there a risk of addiction to ketamine during the treatment of depression? J Psychopharmacol 39. DOI: 10.1177/02698811241303597.

Palamar

Fitzgerald

Grundy

, et al. (2023) Characteristics of poisonings involving ketamine in the United States, 2019–2021. J Psychopharmacol 37: 802–808.

Pastuszak

Wiglusz

(2023) Comment on “characteristics of poisonings involving ketamine in the United States, 2019–2021.” J Psychopharmacol 37: 845–846.

Phillips

(2024) What is ketamine infusion therapy? BBC News, 16 August, 2024. Available at: https://www.bbc.co.uk/news/articles/ckgw5yky91zo

10.

Rodrigues

Chen-Li

Di Vincenzo

, et al. (2024) Brain-derived neurotrophic factor Val66Met and CYP2B6 polymorphisms as predictors for ketamine effectiveness in patients with treatment-resistant depression. J Psychopharmacol 38: 375–381.

11.

Szarmach

Cubała

Włodarczyk

, et al. (2021) Somatic comorbidities and cardiovascular safety in ketamine use for treatment-resistant depression. Medicina (Kaunas) 57: 274.

12.

Wilkowska

Włodarczyk

Gałuszko-Węgielnik

, et al. (2021) Intravenous ketamine infusions in treatment-resistant bipolar depression: An open-label naturalistic observational study. Neuropsychiatr Dis Treat 17: 2637–2646.

13.

Włodarczyk

Cubała

Gałuszko-Węgielnik

, et al. (2021) Central nervous system-related safety and tolerability of add-on ketamine to antidepressant medication in treatment-resistant depression: focus on the unique safety profile of bipolar depression. Ther Adv Psychopharmacol 11: 20451253211011021.